Business
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutic
About this update from Coherus Oncology, Inc.
[{"type":"image","alt":"Coherus Oncology, Inc.","displaySize":"","headline":null,"caption":"Coherus Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Oe14ACN4sd6wayCRQj8VlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170","width":300,"height":90}},"lazy":false},{"type":"text","content":"-Coherus Oncology formally introduces non-proprietary name: tagmokitug-","length":76,"tagName":"p"},{"type":"text","content":"-Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies-","length":134,"tagName":"p"},{"type":"text","content":"-Data show CCR8 target is present with high prevalence and density in many solid tumors-","length":88,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and significant effector mediated killing of CCR8+ cells of its investigational anti-CCR8 monoclonal antibody. The findings show that the antibody, now named tagmokitug, demonstrated no off-target binding, and selectively eliminates CCR8+ T regulatory cells and not other T cells, supporting its potential as an anticancer treatment. The full article may be accessed in the December 2025 issue of Molecular Cancer Therapeutics.","length":693,"tagName":"p"},{"type":"text","content":"The publication provides important scientific evidence for the program and supports the ongoing advancement of tagmokitug in clinical studies evaluating its antitumor activity across multiple solid tumor settings in combination with toripalimab.","length":245,"tagName":"p"},{"type":"text","content":"“This publication presents the robust pharmacology of tagmokitug in preclinical and clinical studies, and with a selectivity profile and potent binding and killing of CCR8+ T regulatory cells and not other immune cells. These data provide evidence that tagmokitug has the potential for a differentiated profile,” said Ther...